Nalbuphine versus tramadol for post-operative pain after abdominal surgery in children with cancer
Official title: Comparative Study Between Nalbuphine Versus Tramadol on Post Operative Analgesia in Abdominal Surgery on Pediatric Cancer Patient
Run by National Cancer Institute, Egypt · NCT07110051 · Data updated 2026-11-12
This trial tests whether nalbuphine or tramadol better controls pain after abdominal surgery in children aged 3–12 with cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 3 Years to 12 Years |
| Sex | All |
| Enrollment | 128 (estimated) |
| Sponsor | National Cancer Institute, Egypt Academic / other |
| Locations | 1 site (Cairo) |
| Status | Recruiting |
| Started | January 15, 2025 |
| Main results expected | September 15, 2025 |
| Study ends | October 15, 2025 |
| Registry record updated | August 11, 2025 |
| Trial ID | NCT07110051 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 3–12 years with cancer, ASA class I–III, scheduled for elective abdominal surgery under general anesthesia, who are not allergic to nalbuphine or tramadol and are not on chronic opioids.
✕Probably not a fit
Children outside the 3–12 age range, those allergic to either drug, those already using chronic opioids, or those having emergency procedures are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Children with cancer aged 3–12 who are scheduled for elective abdominal surgery under general anesthesia will receive either nalbuphine or tramadol for postoperative pain management. Investigators will monitor pain scores and common opioid-related side effects such as respiratory depression, nausea/vomiting, and pruritus in the immediate postoperative period. Patients with allergies to the study drugs or on chronic opioid therapy are excluded. The goal is a direct comparison of analgesic effectiveness and safety between the two drugs in this surgical pediatric population.
Why it matters
Potential benefit: If successful, this could identify which opioid provides better pain relief with fewer side effects for children with cancer after abdominal surgery.
How similar studies have gone: Prior adult studies and some pediatric reports show tramadol provides effective analgesia with comparatively fewer adverse effects, but direct head‑to‑head pediatric comparisons with nalbuphine after abdominal surgery are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants will be children aged 3-12 years * American society of anesthesia (ASA) classification I-III. * scheduled for elective Abdominal surgery under general anesthesia Exclusion Criteria: * child guardian refusal. * Allergy from Tramal or nalbuphine * Patient with previous chronic pain on opioids
Where it's running
-
National cancer institute
Cairo, Egypt Recruiting
Study contacts
- Principal investigator: Reham mohamed gamal, MD — assistant professor
- Study coordinator: Norma Osama AbdAllah Zayed, MD
- Email: norma.osama@nci.cu.edu.eg
- Phone: 01067843111
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
FaceSay: a computer program to help kids recognize facial expressions and improve social interactions
A computer-based FaceSay program is tested to see if it helps survivors of pediatric brain tumors who have social difficulties see facial expressions better and relate more comfortably with peers.
-
Tramadol vs Morphine for Postoperative Pain After Laparoscopic Abdominal Surgery
This study tests whether tramadol can provide comparable pain relief to morphine after laparoscopic abdominal surgery when used as part of multimodal pain management.
-
Access to Innovative Cancer Treatments for Children and Young People in Belgium
This observational study collects safety and effectiveness data on off‑label and compassionate cancer medicines used in kids and young adults up to age 25 in Belgium.
-
BCB-276 CAR T therapy for DIPG in children and young adults
This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.
-
CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes
This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.
-
Virtual reality headsets to reduce anxiety and fear during intrathecal chemotherapy in children
This project will try virtual reality headsets with children aged 4–10 who are receiving intrathecal chemotherapy to see if they reduce anxiety, fear, and changes in vital signs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.